5245582025-10-012025-12-315245582025-04-012025-12-315245582025-10-012025-12-31in-capmkt:OtherExpenses1Member5245582025-10-012025-12-31in-capmkt:OtherExpenses2Member5245582025-04-012025-12-31in-capmkt:OtherExpenses1Member5245582025-04-012025-12-31in-capmkt:OtherExpenses2Member5245582025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15245582025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15245582025-10-012025-12-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares524558NEULANDLABNOTLISTEDINE794A01010NEULAND LABORATORIES LIMITEDMain BoardEquity2025-04-012026-03-312026-02-092026-01-21INRLakhsQuarterlyThird quarterSingle segmentManufacturing of Active Pharmaceuticals2026-02-0914:45:002026-02-0915:45:00Declaration of unmodified opinionfalsefalseNot Applicable2025-10-012025-12-31UnauditedStandalone439709300080524000447761700019985540000-1079690008599370006790000023917400087731300039349090005427080000542708000152058000-1350500013855300004041550000000404155000-18620004022930001290050001031.531.50031.531.51. The financial results for the quarter and nine months ended December 31, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 9, 2026. <BR> <BR> 2. The financial results have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. <BR> <BR> 3. The operations of the Company are predominantly related to the manufacture and sale of active pharmaceutical ingredients and allied services. As such there is only one primary reportable segment as per Ind AS 108 "Operating Segments". In accordance with Ind AS 108 - 'Operating segments', segment information has been given in the unaudited consolidated financial results of the Company and therefore no separate disclosure on segment information is given in these unaudited standalone financial results. <BR> <BR> 4. During the previous year, the Company has fully transferred an investment property located in Nanakramguda, Hyderabad, Telangana, through perpetual lease, resulting in total profit of Rs. 7,640.36 lakhs (For the quarter ended June 30, 2024: Rs. 2,062.56 lakhs and for the quarter ended December 31, 2024: Rs. 5,577.80 lakhs) being the profit is exceptional in nature, it has been disclosed as a separate line item. <BR> <BR> 5. The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four labour codes, which have been effective from November 21, 2025. The incremental impact of these changes have been recognised in the financial results of the Company for the quarter and nine months ended December 31, 2025 which is not material. <BR> <BR> 6. The EPS for quarters has not been annualised.2025-04-012025-12-31UnauditedStandalone124673510001770700001264442100058897580000-10276440002335545000167145000666438000260627700010637519000200690200002006902000520851000-197680005010830000150581900000001505819000-4789000150103000012900500010117.37117.3700117.37117.37Manufacturing expense545612000Other Expenses331701000Manufacturing expense1398922000Other Expenses1207355000Re-measurement gain/(loss) on defined benefit plans-2489000-2489000Re-measurement gain/(loss) on defined benefit plans-6400000-6400000-627000-161100000-1862000-4789000UnauditedfalseM S K A & Associates LLP, Chartered Accountantstrue2027-07-31